About RTX-240 Clinical Trials

Participating in a clinical trial is a significant commitment.
We are grateful for the important contributions of the volunteers who take part in this important research.

About the RTX-240
phase 1/2 clinical trial

This Phase 1/2 clinical trial is designed to establish whether RTX‑240 is safe, how much RTX‑240 needs to be given for it to be effective, and how often it should be given to be effective. The trial seeks to evaluate:

  • Any side effects associated with RTX‑240
  • Preliminary dose and schedule, meaning how much RTX‑240 needs to be given for it to be effective, and how often it should be given to be effective

All study participants
receive at no cost:

The study drug, study-related services, supplies, procedures, and care performed as part of this study and not part of your routine medical care will be paid for by the study site, through the study Sponsor.

Who can participate?

Upon reviewing the clinical trial eligibility criteria, speak with your doctor about any questions you may have and clinical trials that may benefit you.

Adults who meet the following criteria may be able to participate in the trial. We cannot guarantee all those who qualify will be selected.

For the solid tumor arm of the trial:

  • Men and women aged 18 or older with a solid tumor cancer that has not responded to treatment or returned following treatment or is locally advanced or cannot be removed through surgery for which no standard therapy exists, or for which the patient is ineligible or has declined standard therapy.
  • Participants must have completed prior therapy, including radiation, at least 28 days prior to study treatment.
  • For females of reproductive potential, agreement to use highly effective contraceptive throughout and for six months following last dose study treatment.

What to expect if you are enrolled

Screening and eligibility
(Up to 28 Days Prior to Receiving a Dose of RTX-240)

Participants in the trial will
undergo:

  • A doctor’s exam
  • Blood tests
First treatment days

Patients will receive RTX-240 until the time in which the disease progresses or in the event of undesirable toxicities.

During the first week, patients will come in for the first three days, and then weekly for the rest of the cycle.

Follow-up visits

In cycle one, after the first three days, weekly visits are required.

In subsequent cycles, patients come in on day one of dosing and day three, followed by weekly visits.

Dosing days take approximately four to six hours, with subsequent visits to take approximately one hour.

Trial site locations

The Angeles Clinic & Research Institute

Los Angeles, California,

United States, 90025

 

Contact: Saba Mukarram

310-231-2181

SMukarram@theangelesclinic.org

Columbia University Medical Center 

New York, New York,

United States, 10032

 

Contact: Research Nurse Navigator

212-342-5162

Cancerclinicaltrials@cumc.columbia.edu

Massachusetts General Hospital

Boston, Massachusetts,

United States, 02114

 

Contact: Ryan Sullivan, MD

617-724-5197

rsullivan7@mgh.harvard.edu

Oregon Health & Sciences University – Knight Cancer Institute

Portland, Oregon,

United States, 97239

 

Contact: Knight Cancer Institute Clinical Trials

trials@ohsu.edu

Sarah Cannon Research Institute

Nashville, Tennessee,

United States, 37203

 

Contact: Sarah Cannon Research Site

615-329-7478

CANN.ResearchReferrals@scresearch.net

Sylvester Comprehensive Cancer Center/UMHC
Miami, Florida,

United States, 33136

 

Contact: Jaime Merchan, MD

305-243-1287

Merchan2@med.miami.edu

Virginia Cancer Specialists  

Fairfax, Virginia,

United States, 22031

 

Contact: Alexander Spira, MD, PhD, FACP

703-280-5390

Alexander.spira@usoncology.com

UPMC Hillman Cancer Center    

Pittsburgh, Pennsylvania,

United States, 15232

 

Contact: Sarah Brodeur

412-623-2944

Brodeurs@upmc.edu